TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05665985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moringa Oleifera
Description: Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moringa Oleifera
Description: Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
Study: NCT06337851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous burr hole craniostomy
Description: Patients in group-1 were fixed in supine position with their heads in neutral and flexion position. Bilateral burr holes were made one after another, the dural surfaces were exposed at the same time, then the outer membranes of both sides opened and hematomas evacuated simultaneously. All the patients underwent a drainage system, performed with the insertion of a silicone tube into the subdural space and tunneled under the scalp to the exit point.
Study: NCT02070380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MultiHance 0.1 mmol/kg
Description: MultiHance administered at 0.1 mmol/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiHance 0.1 mmol/kg
Description: MultiHance administered at 0.1 mmol/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dotarem
Description: Dotarem administered at 0.1 mmol/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dotarem
Description: Dotarem administered at 0.1 mmol/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Dotarem administered at 0.1 mmol/kg
Study: NCT06337851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consecutive burr hole craniostomy
Description: In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated. The contralateral hematoma was evacuated.
Study: NCT05611463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Plus Docetaxel and Cisplatin
Description: Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
Study: NCT03595215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation
Study: NCT03903029

Intervention type: DRUG
Intervention: Low-dose (10mg) rosuvastatin
Description: Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
Study: NCT03819946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: esophageal cooling device (Attune Medical, Chicago, IL)
Description: The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard esophageal temperature probe
Description: If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
Study: NCT03502707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
Study: NCT02070380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Dotarem administered at 0.1 mmol/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MultiHance 0.05 mmol/kg
Description: MultiHance administered at 0.05 mmol/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiHance 0.05 mmol/kg
Description: MultiHance administered at 0.05 mmol/kg
Study: NCT03023683

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: Influenza Virus Vaccine Live, Intranasal Spray

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: Influenza Virus Vaccine Live, Intranasal Spray
Study: NCT02540902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All-polyethylene tibia (Aesculap AG)
Description: Implantation of an all polyethylene tibial component.
Study: NCT03502707

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
Study: NCT01253330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message Reminders
Description: During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
Study: NCT03385642

Intervention type: DEVICE
Intervention: ChondroMimetic
Description: ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
Study: NCT01560559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy
Description: An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.~This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips.
Study: NCT02544087

Intervention type: DRUG
Group type: OTHER
Intervention: Ixeris of sonchifolia Hance
Description: KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.

Intervention type: DRUG
Group type: OTHER
Intervention: Panax notoginseng saponins
Description: Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Study: NCT04590079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional pain treatment with daily sessions with innovative medical device, Remedee One, for pain management by Millimeter Band Radiation
Description: Conventional pain treatement with daily sessions with innovative medical device for pain management (radiation in millimeter band) at the rate of 1 to 3 sessions by day of 40 minutes for 3 months.
Study: NCT02544087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixeris of sonchifolia Hance combined with Panax notoginseng saponins
Description: KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Study: NCT01772693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial MRgFUS
Description: ExAblate Transcranial MR Guided Focused Ultrasound

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ExAblate Transcranial MRgFUS
Description: Sham ExAblate Transcranial MR Guided Focused Ultrasound
Study: NCT03090542

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: clinoptilolite
Description: randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
Study: NCT02719574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-2102 (olutasidenib)
Description: FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine will be administered per site's standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine will be administered per site's standard of care
Study: NCT03413371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
Study: NCT03502707

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
Study: NCT03413371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
Study: NCT03502707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
Study: NCT02719574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine will be administered per site's standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine will be administered per site's standard of care
Study: NCT02719574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine will be administered per site's standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: low-dose cytarabine will be administered per site's standard of care
Study: NCT04236414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to \<18 years. AAF available for ≥0.5 to \<6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to \<18 years. AAF available for ≥0.5 to \<6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to \<18 years. AAF available for ≥0.5 to \<6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to \<18 years. AAF available for ≥0.5 to \<6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.
Study: NCT00253955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Study: NCT04410133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F fluciclovine
Description: 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
Study: NCT03502707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
Study: NCT01665794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide taken orally at assigned dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide taken orally at assigned dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib given by intravenous (IV) infusion at assigned dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib given by intravenous (IV) infusion at assigned dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone taken orally of given by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone taken orally of given by IV infusion.
Study: NCT00757107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taperloc Microplasty
Description: primary total hip arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taperloc standard
Description: primary total hip arthroplasty
Study: NCT03492411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth Breastfeeding Co-parenting Resource
Description: The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
Study: NCT01111409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFIX Device
Description: Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor